T1	Participants 117 245	Thirty patients (mean age: 10.38 years) affected by primary headache were selected for a double-blind cross-over clinical trial.
T2	Participants 246 459	The patients were randomized into 2 homogeneous groups of 15 and treated for 12 weeks with L-5-HTP (100 mg/day) and placebo as per the following design: placebo - L-5-HTP (group A) and L-5-HTP - placebo (group B).
